These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Lubiprostone for constipation and irritable bowel syndrome with constipation. Tuteja AK; Rao SS Expert Rev Gastroenterol Hepatol; 2008 Dec; 2(6):727-33. PubMed ID: 19090733 [TBL] [Abstract][Full Text] [Related]
6. Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome. Raschi E; De Ponti F Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):293-305. PubMed ID: 24387275 [TBL] [Abstract][Full Text] [Related]
7. Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome. Schey R; Rao SS Dig Dis Sci; 2011 Jun; 56(6):1619-25. PubMed ID: 21523369 [TBL] [Abstract][Full Text] [Related]
8. Lubiprostone: a chloride channel activator for treatment of chronic constipation. Ambizas EM; Ginzburg R Ann Pharmacother; 2007 Jun; 41(6):957-64. PubMed ID: 17519292 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. Fukudo S; Hongo M; Kaneko H; Ueno R Neurogastroenterol Motil; 2011 Jun; 23(6):544-e205. PubMed ID: 21303430 [TBL] [Abstract][Full Text] [Related]
10. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. Gale JD Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393 [TBL] [Abstract][Full Text] [Related]
14. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Chey WD; Drossman DA; Johanson JF; Scott C; Panas RM; Ueno R Aliment Pharmacol Ther; 2012 Mar; 35(5):587-99. PubMed ID: 22251419 [TBL] [Abstract][Full Text] [Related]
15. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents. Thomas RH; Luthin DR Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701 [TBL] [Abstract][Full Text] [Related]
16. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome. Chamberlain SM; Rao SS Expert Opin Drug Saf; 2012 Sep; 11(5):841-50. PubMed ID: 22834474 [TBL] [Abstract][Full Text] [Related]
17. A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly. Gras-Miralles B; Cremonini F Clin Interv Aging; 2013; 8():191-200. PubMed ID: 23439964 [TBL] [Abstract][Full Text] [Related]
18. Lubiprostone for the treatment of opioid-induced bowel dysfunction. Wong BS; Camilleri M Expert Opin Pharmacother; 2011 Apr; 12(6):983-90. PubMed ID: 21385112 [TBL] [Abstract][Full Text] [Related]
19. Lubiprostone: a novel treatment for chronic constipation. Lacy BE; Levy LC Clin Interv Aging; 2008; 3(2):357-64. PubMed ID: 18686757 [TBL] [Abstract][Full Text] [Related]
20. Lubiprostone: in constipation-predominant irritable bowel syndrome. Carter NJ; Scott LJ Drugs; 2009 Jun; 69(9):1229-37. PubMed ID: 19537839 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]